Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ruxolitinib + RVU120 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RVU120 | SEL120|SEL 120-34|SEL120-34A|RVU 120|RVU-120 | CDK8 Inhibitor 5 | RVU120 (SEL120) selectively inhibits CDK8, resulting in decreased STAT5 and STAT1 phosphorylation and downstream signaling, and potentially leading to reduced tumor cell growth (PMID: 28422713). | |
| Ruxolitinib | Jakafi | INCB 18424|INCB018424|INCB18424 | JAK1 Inhibitor - ATP competitive 5 JAK2 Inhibitor - ATP competitive 15 | Jakafi (ruxolitinib) is an inhibitor of protein tyrosine kinases JAK1 and JAK2, thus resulting in reduced inflammation and reduced proliferation (PMID: 22474318). Jakafi (ruxolitinib) is FDA approved to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis (FDA.gov) |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06397313 | Phase II | RVU120 Ruxolitinib + RVU120 | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (POTAMI-61) | Recruiting | POL | ITA | 0 |